Protein C Activity

What the laboratory says this test is for

This panel evaluates for the most common hereditary and acquired venous thrombophilia risk factors.

What the laboratory says this test is for

Factor V Leiden (R506Q) is the most common genetic determinant for hereditary venous thrombosis. Another DNA variant, the HR2 allele, has been associated with a 3-4 fold increased risk to venous thrombosis when it occurs in the presence of the Factor V Leiden mutation.

What the laboratory says this test is for

This panel is useful to determine the etiology of various hypercoagulability states.

What the laboratory says this test is for

Aids in characterization of protein C deficiency. Type I deficiency is characterized by reduction in activity (functional) and antigen levels. With type II deficiency (dysfunctional protein), antigen levels may be normal and activity levels are decreased. Acquired deficiencies may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn. Drug therapy with L-asparaginase or fluorouracil can also reduce Protein C antigen levels.Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K Antagonists (eg coumadin): decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Direct Thrombin Inhibitors): may falsely increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.

What the laboratory says this test is for

Protein C (PC) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PC deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn.Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K antagonists (eg warfarin): decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.

What the laboratory says this test is for

This profile examines the most common hereditary and acquired thrombophilia risk factors associated with recurrent miscarriage or stillbirth.

What the laboratory says this test is for

This panel evaluates for the most common hereditary and acquired venous thrombophilia risk factors.

What the laboratory says this test is for

Protein C (PC) and Protein S (PS) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PC or PS deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn. In addition, PS deficiency is physiologic in pregnancy. ⁠⁠⁠⁠⁠⁠⁠Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Direct Thrombin Inhibitors): may falsely increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.